Gibb Jean, Wong Darren W
Division of Infectious Diseases, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA 90033, USA.
Antibiotics (Basel). 2021 Oct 9;10(10):1226. doi: 10.3390/antibiotics10101226.
is an urgent global threat due to its increasing incidence and intrinsic antibiotic resistance. Antibiotic development has focused on carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter, with approved antibiotics in recent years having limited activity for Stenotrophomonas. Accordingly, novel treatment strategies for Stenotrophomonas are desperately needed. We conducted a systemic literature review and offer recommendations based on current evidence for a treatment strategy of Stenotrophomonas infection.
由于其发病率不断上升以及固有的抗生素耐药性，它已成为全球紧迫的威胁。抗生素研发主要集中在耐碳青霉烯类肠杆菌科细菌、铜绿假单胞菌和不动杆菌，近年来获批的抗生素对嗜麦芽窄食单胞菌的活性有限。因此，迫切需要针对嗜麦芽窄食单胞菌的新型治疗策略。我们进行了一项系统的文献综述，并根据当前证据对嗜麦芽窄食单胞菌感染的治疗策略提出建议。
